Simultaneous RZV and aIIV4 Vaccination
Safety of Simultaneous Vaccination With Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (aIIV4)
Sponsor: Centers for Disease Control and Prevention
Listed as NCT05007041, this PHASE4 trial focuses on Adverse Drug Event and Injection Site Reaction and remains completed. Sponsored by Centers for Disease Control and Prevention, it has been updated 12 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Jul 2023 — Jun 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE4
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE4
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE4
Status: Suspended → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Suspended PHASE4
Status: Recruiting → Suspended
-
Oct 2021 — Jul 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centers for Disease Control and Prevention
- Duke University
- Johns Hopkins University
For direct contact, visit the study record on ClinicalTrials.gov .